Telomir director granted 50,000 stock options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Telomir Pharmaceuticals director Whalen Matthew Pratt received a grant of 50,000 Non-Qualified Stock Options on April 16, 2026. The options have an exercise price of $1.3400 per share, expire on April 16, 2036, were granted under the 2023 Omnibus Incentive Plan, vested immediately, and leave him holding 50,000 derivative securities directly.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Non-Qualified Stock Options (right to buy) F1, F2 | 50,000 | $0.00 | $0.00 |
Footnotes (2)
- F1. The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on April 16, 2026.
- F2. The stock options were issued to the Reporting Person on April 16, 2026, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). All of the options vested immediately upon issuance.
Key Figures
Key Terms
Non-Qualified Stock Options financial
exercise price financial
2023 Omnibus Incentive Plan financial
vested financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What transaction did Telomir Pharmaceuticals (TELO) report for Whalen Matthew Pratt?
What is the exercise price of the new TELO options granted to Whalen Matthew Pratt?
When do Whalen Matthew Pratt’s Telomir (TELO) stock options expire?
How quickly did the Telomir (TELO) options granted to Whalen Matthew Pratt vest?
How many Telomir (TELO) derivative securities does Whalen Matthew Pratt hold after this grant?
Was the Telomir (TELO) options grant to Whalen Matthew Pratt made under a Rule 10b5-1 plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.